Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Charlaine van Steenis"'
Autor:
Yuwei Wang, Gwen M. H. E. Dackus, Efraim H. Rosenberg, Sten Cornelissen, Leonora W. de Boo, Annegien Broeks, Wim Brugman, Terry W. S. Chan, Paul J. van Diest, Michael Hauptmann, Natalie D. ter Hoeve, Olga I. Isaeva, Vincent M. T. de Jong, Katarzyna Jóźwiak, Roelof J. C. Kluin, Marleen Kok, Esther Koop, Petra M. Nederlof, Mark Opdam, Philip C. Schouten, Sabine Siesling, Charlaine van Steenis, Adri C. Voogd, Willem Vreuls, Roberto F. Salgado, Sabine C. Linn, Marjanka K. Schmidt
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-14 (2024)
Abstract Background Due to the abundant usage of chemotherapy in young triple-negative breast cancer (TNBC) patients, the unbiased prognostic value of BRCA1-related biomarkers in this population remains unclear. In addition, whether BRCA1-related bio
Externí odkaz:
https://doaj.org/article/ddff242b9c864f39864f3885aee7bad4
Autor:
Jeroen van Dorp, Christodoulos Pipinikas, Britt B. M. Suelmann, Niven Mehra, Nick van Dijk, Giovanni Marsico, Maurits L. van Montfoort, Sophie Hackinger, Linde M. Braaf, Tauanne Amarante, Charlaine van Steenis, Kirsten McLay, Antonios Daletzakis, Daan van den Broek, Maaike W. van de Kamp, Kees Hendricksen, Jeantine M. de Feijter, Thierry N. Boellaard, Richard P. Meijer, Toine G. van der Heijden, Nitzan Rosenfeld, Bas W. G. van Rhijn, Greg Jones, Michiel S. van der Heijden
Publikováno v:
Nature Medicine, 29, 3, pp. 588-592
Nature Medicine, 29, 588-592
Nature Medicine, 29, 588-592
Item does not contain fulltext Cohort 1 of the phase 1B NABUCCO trial showed high pathological complete response (pCR) rates with preoperative ipilimumab plus nivolumab in stage III urothelial cancer (UC). In cohort 2, the aim was dose adjustment to
Autor:
Leonora W. de Boo, Katarzyna Jóźwiak, Heikki Joensuu, Henrik Lindman, Susanna Lauttia, Mark Opdam, Charlaine van Steenis, Wim Brugman, Roelof J. C. Kluin, Philip C. Schouten, Marleen Kok, Petra M. Nederlof, Michael Hauptmann, Sabine C. Linn
BackgroundThe addition of adjuvant capecitabine to standard chemotherapy of early-stage triple-negative breast cancer (TNBC) patients has improved survival in a few randomised trials and in meta-analyses. However, many patients did not benefit. We ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1d5aae5b49887e291215b9d10757ac1
http://hdl.handle.net/10138/343740
http://hdl.handle.net/10138/343740
Autor:
Michael Hauptmann, Mark Opdam, Henrik Lindman, Petra M. Nederlof, Philip C. Schouten, Susanna Lauttia, Charlaine van Steenis, H Joensuu, Wim Brugman, Marleen Kok, Leonora W. de Boo, Sabine C. Linn, Katarzyna Jóźwiak, Roelof J.C. Kluin
Background: Recent data demonstrate that patients with early-stage triple negative breast cancer (TNBC) benefit from escalating adjuvant treatment with capecitabine. However, since a substantial proportion of patients does not benefit, predictive bio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ca5599b9be139ac657742f8bc173a4e
https://doi.org/10.21203/rs.3.rs-125140/v1
https://doi.org/10.21203/rs.3.rs-125140/v1